Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Montecinos, Viviana P ^a,b   Godoy, Alejandro ^a   Hinklin, Jennifer ^a   Vethanayagam, R Robert ^a   Smith, Gary J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANDROGEN; CALPONIN; DESMIN; DYE; TENASCIN; TESTOSTERONE; TRICHROME; UNCLASSIFIED DRUG; VASCULOTROPIN A; VIMENTIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TUMOR MARKER;

ANASTOMOSIS; ANGIOGENESIS; ARTICLE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; INTERSTITIUM; MALE; PERICYTE; PHENOTYPE; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; STROMA; TUMOR XENOGRAFT; UPREGULATION; VASCULARIZATION; ANIMAL; BIOLOGICAL MODEL; CELL HYPOXIA; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; METABOLISM; MOUSE; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSTATE; STROMA CELL; TIME;

MUS;

ANASTOMOSIS, SURGICAL; ANDROGENS; ANIMALS; CELL HYPOXIA; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, SCID; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; STROMAL CELLS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856446095     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029623     Document Type: Article

References (64)

1. Carmeliet P, Jain RK, (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257.
2. Folkman J, (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
3. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J, (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409.
4. Vartanian RK, Weidner N, (1995) Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. Lab Invest 73: 844-850.
5. Lissbrant IF, Stattin P, Damber JE, Bergh A, (1997) Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate 33: 38-45.
6. Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW, (1998) CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 160: 459-465.
7. Lissbrant IF, Lissbrant E, Damber JE, Bergh A, (2001) Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 35: 437-452.
8. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E, (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165.
9. Lissbrant IF, Lissbrant E, Persson A, Damber JE, Bergh A, (2003) Endothelial cell proliferation in male reproductive organs of adult rat is high and regulated by testicular factors. Biol Reprod 68: 1107-1111.
10. Shabsigh A, Chang DT, Heitjan DF, Kiss A, Olsson CA, et al. (1998) Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 36: 201-206.
11. Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, et al. (1998) Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 95: 10820-10825.
12. Sordello S, Bertrand N, Plouet J, (1998) Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 251: 287-290.
13. Hanahan D, Folkman J, (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
14. Jung YD, Ahmad SA, Liu W, Reinmuth N, Parikh A, et al. (2002) The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Semin Cancer Biol 12: 105-112.
15. Godoy A, Watts A, Sotomayor P, Montecinos VP, Huss WJ, et al. (2008) Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell. Endocrinology 149: 2959-2969.
16. Morrison C, Cheney R, Johnson CS, Smith G, Mohler JL, (2009) Central quadrant procurement of radical prostatectomy specimens. Prostate 69: 770-773.
17. Gray DR, Huss WJ, Yau JM, Durham LE, Werdin ES, et al. (2004) Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Res 64: 1712-1721.
18. Presnell SC, Werdin ES, Maygarden S, Mohler JL, Smith GJ, (2001) Establishment of short-term primary human prostate xenografts for the study of prostate biology and cancer. Am J Pathol 159: 855-860.
19. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, et al. (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116: 2610-2621.
20. Haggstrom S, Lissbrant IF, Bergh A, Damber JE, (1999) Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. J Urol 161: 1620-1625.
21. Haggstrom S, Wikstrom P, Bergh A, Damber JE, (1998) Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. Prostate 36: 71-79.
22. Joseph IB, Isaacs JT, (1997) Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 57: 1054-1057.
23. Thurston G, Baluk P, Hirata A, McDonald DM, (1996) Permeability-related changes revealed at endothelial cell borders in inflamed venules by lectin binding. Am J Physiol 271: H2547-2562.
24. Hellstrom M, Gerhardt H, Kalen M, Li X, Eriksson U, et al. (2001) Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 153: 543-553.
25. Lissbrant IF, Hammarsten P, Lissbrant E, Ferrara N, Rudolfsson SH, et al. (2004) Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice. Prostate 58: 57-65.
26. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, et al. (2003) The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4: 133-146.
27. Pugh CW, Ratcliffe PJ, (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9: 677-684.
28. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, et al. (2003) Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 9: 4792-4801.
29. Dvorak HF, (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650-1659.
30. Garber K, (2009) From human to mouse and back: 'tumorgraft' models surge in popularity. J Natl Cancer Inst 101: 6-8.
31. Weinberg RA, (2007) Dailogue Replaces Monologue: Heterotypic Interactions and the Biology of Angiogenesis. In: Weinberg RA, editors. The Biology of Cancer New York Garland Science, Taylor & Francis Group, LLC pp. 527-586.
32. Bergers G, Hanahan D, (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
33. Ebos JM, Kerbel RS, (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8: 316.
34. Ellis LM, Hicklin DJ, (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591.
35. Cascone T, Herynk MH, Xu L, Du Z, Kadara H, et al. (2011) Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 121: 1313-1328.
36. Francia G, Emmenegger U, Kerbel RS, (2009) Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy. Cancer Cell 15: 3-5.
37. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, et al. (2007) Autocrine VEGF signaling is required for vascular homeostasis. Cell 130: 691-703.
38. Godoy A, Montecinos VP, Gray DR, Sotomayor P, Yau JM, et al. (2011) Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab 300: E263-275.
39. Alonzi R, Padhani AR, Taylor NJ, Collins DJ, D'Arcy JA, et al. (2011) Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. Int J Radiat Oncol Biol Phys 80: 721-727.
40. Kravchick S, Cytron S, Mamonov A, Peled R, Linov L, (2009) Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study. Urology 73: 1274-1278.
41. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, et al. (1999) VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J 18: 3964-3972.
42. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, et al. (2006) VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124: 175-189.
43. Nicholson B, Theodorescu D, (2004) Angiogenesis and prostate cancer tumor growth. J Cell Biochem 91: 125-150.
44. Benjamin LE, Keshet E, (1997) Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A 94: 8761-8766.
45. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, et al. (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165: 35-52.
46. Pettersson A, Nagy JA, Brown LF, Sundberg C, Morgan E, et al. (2000) Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 80: 99-115.
47. Phung TL, Eyiah-Mensah G, O'Donnell RK, Bieniek R, Shechter S, et al. (2007) Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. Cancer Res 67: 5070-5075.
48. Sundberg C, Nagy JA, Brown LF, Feng D, Eckelhoefer IA, et al. (2001) Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol 158: 1145-1160.
49. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, et al. (2008) A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456: 809-813.
50. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D, (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287-1295.
51. Sun J, Wang DA, Jain RK, Carie A, Paquette S, et al. (2005) Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene 24: 4701-4709.
52. Pietras K, Hanahan D, (2005) A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23: 939-952.
53. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, et al. (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59: 5002-5011.
54. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348.
55. Tuxhorn JA, Ayala GE, Rowley DR, (2001) Reactive stroma in prostate cancer progression. J Urol 166: 2472-2483.
56. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, et al. (2002) Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 8: 2912-2923.
57. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, et al. (2004) Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2: E7.
58. Basanta D, Strand DW, Lukner RB, Franco OE, Cliffel DE, et al. (2009) The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach. Cancer Res 69: 7111-7120.
59. Reinders ME, Fang JC, Wong W, Ganz P, Briscoe DM, (2003) Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection. Transplantation 76: 224-230.
60. Reinders ME, Sho M, Izawa A, Wang P, Mukhopadhyay D, et al. (2003) Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 112: 1655-1665.
61. Torry RJ, Labarrere CA, Torry DS, Holt VJ, Faulk WP, (1995) Vascular endothelial growth factor expression in transplanted human hearts. Transplantation 60: 1451-1457.
62. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, et al. (1998) Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 152: 1445-1452.
63. Dvorak HF, (2003) Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol 162: 1747-1757.
64. Pinto MP, Badtke MM, Dudevoir ML, Harrell JC, Jacobsen BM, et al. (2010) Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer. Cancer Res 70: 2655-2664.